(object) array( 'id' => '6229774', 'url' => 'FR/clinical_trial_₁₁', 'image' => '', 'title' => 'Essai clinique', 'tags' => array ( 0 => 'Essai clinique', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Essai clinique', 'source_id' => 4011597, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104712', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une étude clinique dans laquelle les participants sont assignés à recevoir une ou plusieurs interventions (ou pas d\'intervention) afin que les chercheurs puissent évaluer les effets des interventions sur les résultats biomédicaux ou liés à la santé. Les assignations sont déterminées par le protocole d\'étude. Les participants peuvent recevoir des interventions diagnostiques, thérapeutiques ou d\'autres types d\'interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081755480064, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A clinical study in which participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study protocol. Participants may receive diagnostic, therapeutic, or other types of interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'interventional_study', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'clinical trial', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'clinical_trial_₁₁', )

(object) array( 'id' => '3951178', 'url' => 'FR/superbug', 'image' => 'Superbug.jpg;', 'title' => 'Superbactéries', 'tags' => array ( 0 => 'Superbactéries', 1 => 'Pharmaceutical', 2 => '', ), 'term' => 'Superbactéries', 'source_id' => 275134, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Bactéries résistantes à presque tous les antibiotiques. Les gènes peuvent être transférés entre les bactéries par conjugaison, transduction ou transformation. Cela signifie que les gènes de résistance aux antibiotiques peuvent se lier à de nombreux types de germes courants et leur confèrent une importante résistance aux médicaments, en créant de superbactéries dangereuses. La dernière épidémie de superbactéries implique des patients qui ont voyagé en Inde où il y a une surpopulation et un usage excessif établi des antibiotiques. Beaucoup de gens en Inde manquent également d\'eau potable et ont des diarrhées répandues ; ce sont des conditions idéales pour la création de superbactéries.', 'usage_comment' => '', 'glossary' => '', 'width' => 450, 'height' => 362, '_version_' => 1507294573051772929, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'superbug', 'Definition' => 'Bacteria resistant to nearly all antibiotics. Genes can be transferred between bacteria by conjugation, transduction, or transformation. This means antibiotic resistance genes can hitch onto many types of common germs and confers broad drug resistance, creating dangerous superbugs. The latest outbreak of superbugs involve patients who have travel to India with an overpopulation and documented overuses antibiotics. Many people in India also lack clean water and have widespread diarrhea disease, which are ideal conditions for the creation of the superbug', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'super bacteria_₀; super bug_₀', 'Sample Image' => 'Superbug.jpg;', 'Industry' => 'Pharmaceutical', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Bethsm', 'Creation Date' => '2010/9/14', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'superbug', )

(object) array( 'id' => '6228620', 'url' => 'FR/primary_outcome_measure', 'image' => '', 'title' => 'Critère de jugement principal', 'tags' => array ( 0 => 'Critère de jugement principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critère de jugement principal', 'source_id' => 4011188, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104701', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le critère de jugement défini dans le protocole qui est le plus important pour évaluer l\'effet d\'une intervention. La plupart des études cliniques ont un critère de jugement principal, mais certaines peuvent en avoir plusieurs.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081752334336, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The planned outcome measure in the protocol that is the most important for evaluating the effect of an intervention. Most clinical studies have one primary outcome measure, but some may have more than one.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary outcome measure', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_outcome_measure', )

(object) array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', )

(object) array( 'id' => '6228624', 'url' => 'FR/Food_And_Drug_Administration_(FDA)', 'image' => '', 'title' => 'Food And Drug Administration (FDA)', 'tags' => array ( 0 => 'Food And Drug Administration (FDA)', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Food And Drug Administration (FDA)', 'source_id' => 4011189, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104702', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une agence du Département de la Santé et des Services sociaux des États-Unis. La FDA est responsable de la protection de la santé publique. Elle se doit d\'assurer la sureté, l\'efficacité et la sécurité des médicaments humains et vétérinaires, des vaccins et autres produits biologiques, des dispositifs médicaux, de l\'approvisionnement alimentaire de la nation, des cosmétiques, des compléments alimentaires et des produits qui émettent des radiations.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081753382912, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'An agency within the U.S. Department of Health and Human Services. FDA is responsible for protecting the public health by making sure that human and veterinary drugs, vaccines and other biological products, medical devices, the nation\'s food supply, cosmetics, dietary supplements, and products that give off radiation are safe, effective, and secure.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'Food And Drug Administration (FDA)', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Food_And_Drug_Administration_(FDA)', )

(object) array( 'id' => '7745593', 'url' => 'FR/study_coordinator', 'image' => '', 'title' => 'Coordinateur de l\'étude clinique', 'tags' => array ( 0 => 'Coordinateur de l\'étude clinique', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Coordinateur de l\'étude clinique', 'source_id' => 1259718, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un membre du personnel qui, travaillant pour l\'investigateur principal, contacte les patients par rapport à l\'inscription à l\'étude, planifie les rendez-vous, maintient les registres nécessaires et gère le fonctionnement quotidien de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821504, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'study coordinator', 'Definition' => 'A staff person who works for the principal investigator to contact patients about enrolling in the study, schedule appointments, maintain required records and manage the day-to-day operation of the study.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_coordinator', )

(object) array( 'id' => '3898056', 'url' => 'FR/variable_ratio_₁', 'image' => '', 'title' => 'Proportion variable', 'tags' => array ( 0 => 'Proportion variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Proportion variable', 'source_id' => 3744260, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105908', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme de renforcement basé sur la réponse dans lequel le nombre de réponses requises pour un renforcement varie après que chaque renforçateur est présenté. Le nombre moyen de réponses est utilisé pour indexer le programme. Par exemple, un rat peut appuyer sur un levier de renforcement 50 fois, puis 150, 70, 30, et 200. En ajoutant ces besoins de réponse pour un total de 500, puis en divisant par le nombre de réponses distinctes apportées (5), on obtient la valeur du programme, PV 100. 2) Un programme dans lequel une personne est renforcée en effectuant une réponse seulement après avoir effectué un nombre variable de ces réponses sans renforcement. Ce programme induit généralement un rythme élevé et uniforme. Il produit le plus haut rythme de réponses pour les programmes simples.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059393, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A response-based schedule of reinforcement in which the number of responses required for reinforcement changes after each reinforcer is presented. The average number of responses is used to index the schedule. For example, a rat may press a lever for reinforcement 50 times, then 150, 70, 30, and 200. Adding these response requirements for a total of 500, then dividing by the number of separate response runs (5), yields the schedule value, VR 100. 2) A schedule in which people are reinforced for making a response only after they have made a varying number of those responses without reinforcement. This schedule usually causes people to work at a high and uniform rate of speed. It produces the highest rate of responding of the simple schedules.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'ratio schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable ratio', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_ratio_₁', )

(object) array( 'id' => '3898055', 'url' => 'FR/fixed_interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744254, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105907', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps fixe soit passée depuis le renforcement précédent. Ce programme induit généralement une pause après un renforçateur puis une augmentation progressive du rythme d\'émission des réponses jusqu\'à un niveau élevé au moment où le prochain renforçateur est reçu.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059392, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A schedule in which a person is reinforced for the first response after a fixed period of time has passed since the previous reinforcement. This schedule usually causes people to pause after a reinforcer and then to gradually increase their response rate until they are working at a high rate at the moment they receive the next reinforcer.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed_interval_₁', )

(object) array( 'id' => '6229090', 'url' => 'FR/comparison_group_₂', 'image' => '', 'title' => 'Groupe de comparaison', 'tags' => array ( 0 => 'Groupe de comparaison', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Groupe de comparaison', 'source_id' => 4011326, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104707', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un groupe de participants à une étude clinique qui est utilisé pour synthétiser les données recueillies lors de l\'étude. Ce groupe peut être identique ou différent d\'un bras de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431488, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A grouping of participants in a clinical study that is used in summarizing the data collected during the study. This grouping may be the same as or different from a study arm.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'reporting_group', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'comparison group', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'comparison_group_₂', )

(object) array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', )